BCDA — BioCardia, Inc.

Summary of BioCardia (BCDA) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Expenses: Increased by approximately 3% year-over-year to $8.3 million in 2025, up from $8.1 million in 2024.
• R&D Expenses: Rose to $5 million in 2025 from $4.4 million in 2024, primarily due to trial closeout activities and regulatory efforts in Japan.
• SG&A Expenses: Decreased by 10% to $3.3 million from $3.7 million in 2024, attributed to lower professional fees and reduced share-based compensation.
• Net Loss: Increased slightly to $8.2 million from $7.9 million in 2024.
• Cash Position: Ended 2025 with $2.5 million in cash and cash equivalents, comparable to $2.4 million at the end of 2024. Net cash used in operations was approximately $7.5 million, down from $7.9 million in 2024.

2. Strategic Updates and Business Highlights

• Therapeutic Platforms: BioCardia is focused on three primary platforms: CardiAMP (autologous cell therapy), CardiALLO (allogeneic cell therapy), and Helix (delivery system).
• CardiAMP HF Trial Results: Presented promising data from three clinical trials, showing reductions in left ventricular volume and improved clinical outcomes, particularly in patients with elevated biomarkers of heart stress.
• Regulatory Engagement: Plans to submit a Q-sub request to the FDA for CardiAMP's approval and discussions with Japan's PMDA regarding the acceptability of existing clinical data for approval.
• CardiAMP HF II Trial: Initiated to focus on patients who are the greatest responders, with four centers actively enrolling patients.

3. Forward Guidance and Outlook

• Upcoming Catalysts: Anticipates four key developments in the next quarter, including:
  • FDA submission for CardiAMP HF approval.
  • Formal consultation with Japan's PMDA.
  • Feedback meeting with the FDA on the Helix delivery system.
  • Presentation of data at EuroPCR in May.
• R&D Expense Outlook: Expected to increase modestly in 2026 as the company advances its therapeutic candidates.

4. Bad News, Challenges, or Points of Concern

• Enrollment Challenges: Enrollment in the CardiAMP HF II trial is progressing slowly due to resource allocation towards regulatory submissions.
• Competitive Landscape: Other companies are pursuing similar cell therapies for heart failure, which could impact market share and approval timelines.
• Financial Position: While cash burn has decreased, the company’s cash reserves remain limited, which may constrain growth and operational flexibility.

5. Notable Q&A Insights

• Echocardiography Data: The p-values for clinical outcomes in the full population were not statistically significant but showed promising trends, particularly in the subgroup with elevated NT-proBNP levels.
• Regulatory Pathway Expectations: The FDA's review process for CardiAMP is expected to be expedited due to its breakthrough designation, with a potential 45-day turnaround for discussions on approvability.
• Partnership Environment: Interest in partnerships is anticipated to increase, especially following the approval of other cardiac therapies, which may enhance the attractiveness of CardiAMP and its related programs.

Overall, BioCardia is making progress with its clinical programs and regulatory strategies, but faces challenges in enrollment and competition in the heart failure therapy market. The company remains focused on advancing its therapies while managing expenses and cash flow.